What's new?We review the literature comparing the relative efficacy and utility of single‐ and dual‐hormone artificial pancreas systems.The pharmacokinetic profile of glucagon, with rapid onset and short duration of action, confers the major benefit of the dual‐hormone artificial pancreas.The dual‐hormone artificial pancreas is superior to single‐hormone systems in reducing hypoglycaemia overall and during exercise in short‐term studies, whereas there is no strong evidence of added benefit for preventing nocturnal or post‐exercise hypoglycaemia.The relative benefit of each system over the long term for improving HbA1c, preventing severe hypoglycaemia, and affecting quality of life remains unknown.IntroductionThe benefits of tight glycaemic control for reducing microvascular complications and all‐cause mortality in Type 1 diabetes must be balanced with the increased risk of hypoglycaemia and the elevated burden of diabetes self‐management that accompanies intensive glucose control. Moreover, fear of hypoglycaemia often leads to permissive hyperglycaemia, which is reflected in suboptimal HbA1c levels in people with Type 1 diabetes .With advances in technology, including continuous glucose monitoring and continuous subcutaneous insulin infusion (CSII) pumps (‘insulin pumps’), the burden of self‐monitoring capillary blood glucose and of multiple daily subcutaneous insulin injections is reduced. Recent evidence points to increased utilization of these emerging technologies, particularly among the
Diabetic Medicine – Wiley
Published: Jan 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera